Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort

International Journal of Cancer

Volumn 137, Issue 10, 2015, Pages 2443-2453

  Hleyhel, Mira ^a,b   Belot, Aurélien ^c,d,e,f   Bouvier, Anne Marie ^g   Tattevin, Pierre ^h   Pacanowski, Jérôme ⁱ   Genet, Philippe ^j   De Castro, Nathalie ^k   Berger, Jean Luc ^l   Dupont, Caroline ^m   Lavolé, Armelle ⁿ   Pradier, Christian ^o   Salmon, Dominique ^b,p   Simon, Anne ^q   Martinez, Valérie ^r   Spano, Jean Philippe ^a,b,q   Costagliola, Dominique ^a,b   Grabar, Sophie ^a,b,p  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d INSTITUT DE VEILLE SANITAIRE   (France)

^e LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l REIMS UNIVERSITY HOSPITAL   (France)

^m HÔPITAL AMBROISE PARÉ   (France)

ⁿ HÔPITAL TENON   (France)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^p Institut Cochin   (France)

^q PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^r HÔPITAL ANTOINE BÉCLÈRE   (France)

more..

Author keywords

calendar period; cancer; general population; HIV; survival

Indexed keywords

ADULT; AGE; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY; ANUS TUMOR; COMPLICATION; EPIDEMIOLOGY; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; NEOPLASM; PROCEDURES; SURVIVAL; TRENDS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; FEMALE; FRANCE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; SARCOMA, KAPOSI; SURVIVAL ANALYSIS;

EID: 84941927507     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29603     Document Type: Article

References (35)

1. Hleyhel M, Belot A, Bouvier AM, et al., Risk of AIDS-defining cancers among HIV-1-infected patients in france between 1992 and 2009: results from the FHDH-ANRS co4 cohort. Clin Infect Dis 2013; 57: 1638-47.
2. Robbins HA, Shiels MS, Pfeiffer RM, et al., Epidemiologic contributions to recent cancer trends among HIV-infected people in the united states. AIDS 2014; 28: 881-90.
3. Shiels MS, Cole SR, Kirk GD, et al., A Meta-analysis of the incidence of Non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-22.
4. Mocroft A, Vella S, Benfield TL, et al., Changing patterns of mortality across europe in patients infected with HIV-1. The Lancet 1998; 352: 1725-30.
5. Palella FJ, Delaney KM, Moorman AC, et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
6. Weber R, Ruppik M, Rickenbach M, et al., Decreasing mortality and changing patterns of causes of death in the swiss HIV cohort study. HIV Med 2013; 14: 195-207.
7. Grabar S, Lanoy E, Allavena C, et al., Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9: 246-56.
8. Lodi S, Guiguet M, Costagliola D, et al., Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102: 784-92.
9. Pipkin S, Scheer S, Okeigwe I, et al., The effect of HAART and calendar period on kaposi's sarcoma and non-hodgkin lymphoma: results of a match between an AIDS and cancer registry. Aids 2011; 25: 463-71.
10. Chow kU, Mitrou PS, Geduldig K, et al., Changing incidence and survival in patients with AIDS-related non-hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001; 41: 105-16.
11. Dore GJ, Li Y, McDonald A, et al., Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in australia. J Acquir Immune Defic Syndr 2002; 29: 388-95.
12. Diamond C, Taylor TH, Aboumrad T, et al., Changes in acquired immunodeficiency syndrome-related non-hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106: 128-35.
13. Robotin MC, Law MG, Milliken S, et al., Clinical features and predictors of survival of AIDS-related non-hodgkin's lymphoma in a population-based case series in sydney, australia. HIV Med 2004; 5: 377-84.
14. Vaccher E, Spina M, Talamini R, et al., Improvement of systemic human immunodeficiency virus-related Non-hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1556-64.
15. Biggar RJ, Engels EA, Ly S, et al., Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39: 293-99.
16. Gérard L, Galicier L, Boulanger E, et al., Improved survival in HIV-related hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17: 81-87.
17. Hessol NA, Pipkin S, Schwarcz S, et al., The impact of highly active antiretroviral therapy on Non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143-53.
18. Bower M, Powles T, Newsom-Davis T, et al., HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr 2004; 37: 1563-65.
19. Maso LD, Suligoi B, Franceschi S, et al., Survival after cancer in italian persons with AIDS, 1986-2005: a population-based estimation. J Acquir Immune Defic Syndr 2014; 66: 428-35.
20. Mary-Krause M, Grabar S, Lièvre L, et al., Cohort profile: french hospital database on HIV (FHDH-ANRS co4). Int J Epidemiol 2014; 43: 1425-36.
21. Grosclaude P, Remontet L, Belot A, et al., Survie des personnes atteintes de cancer en France, 1989-2007. Institut de veille sanitaire; 2013. Available at: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2013/Survie-des-personnes-atteintes-de-cancer-en-France-1989-2007. (Accessed on April 22, 2015).
22. Jooste V, Grosclaude P, Remontet L, et al., Unbiased estimates of long-term net survival of solid cancers in france. Int J Cancer 2013; 132: 2370-77.
23. Monnereau A, Troussard X, Belot A, et al., Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in france. Int J Cancer 2013; 132: 2378-87.
24. Chao C, Xu L, Abrams D, et al., Survival of non-hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS 2010; 24: 1765-70.
25. 25., Morlat P, et le groupe d'experts. Prise en charge médicale des pesonnes vivant avec le VIH. Recommandations du groupe d'experts sous la direction du Pr Philippe Morlat. Ed. La documentation Française; 2013. Available at: http://www.cns.sante.fr/spip.php?article480. (Accessed on April 22, 2015).
26. Gopal S, Patel MR, Yanik EL, et al., Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. JNCI J Natl Cancer Inst 2013; 105: 1221-9.
27. Suneja G, Shiels MS, Angulo R, et al., Cancer treatment disparities in HIV-infected individuals in the united states. J Clin Oncol 2014; 32: 2344-50.
28. Lavolé A, Chouaïd C, Baudrin L, et al., Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009; 65: 345-50.
29. Lavolé A, Epaud C, Rosencher L, et al., [lung cancer in HIV-positive patients]. Rev Pneumol Clin 2007; 63: 167-75.
30. Spano J-P, Massiani M-A, Bentata M, et al., Lung cancer in patients with HIV infection and review of the literature. Med Oncol 2004; 21: 109-15.
31. Suneja G, Shiels MS, Melville SK, et al., Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27: 459-68.
32. Powles T, Thirwell C, Newsom-Davis T, et al., Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. Br J Cancer 2003; 89: 457-59.
33. Rengan R, Mitra N, Liao K, et al., Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012; 13: 1203-09.
34. Lim C, Goutte N, Gervais A, et al., Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr 2012; 61: 581-87.
35. Oehler-Janne C, Huguet F, Provencher S, et al., HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-57.